Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
502.00
Ask:
503.00
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Board changes

29 Oct 2014 10:00

29 October 2014

Tate & Lyle PLC

Board changes

Tate & Lyle PLC (the “Company”) announces that Paul Forman has been appointed as a Non-Executive Director and a member of the Audit, Remuneration and Nominations Committees with effect from 1 January 2015.

Paul is Group Chief Executive of Coats plc, a leading industrial thread and consumer textile crafts business. Prior to joining Coats in 2009, he was Group Chief Executive of Low & Bonar PLC, a global performance materials group, and was previously Managing Director at Unipart International, a leading European automotive aftermarket supplier. Paul also served as a non-executive director at Brammer PLC from 2006 to 2010.

The Company further announces that Liz Airey, currently Chairman of the Audit Committee, will become Senior Independent Director and Anne Minto will assume the chairmanship of the Remuneration Committee with effect from 1 January 2015, after Robert Walker steps down from the Board following the completion of his term of appointment on 31 December 2014. Douglas Hurt will succeed Liz Airey as Chairman of the Audit Committee with effect from 1 March 2015 and will also replace her as a member of the Corporate Responsibility Committee from that date.

Sir Peter Gershon, Chairman of Tate & Lyle, said "I am delighted that Paul has agreed to join the Board. His wide experience of managing international businesses, developing business-to-business customer and market-led strategies, and commercialising innovation pipelines will be of significant benefit to the Board.

“I would also like to thank Robert for his nine years of exemplary service and significant contribution to the Board and the Remuneration Committee at a critical period in the Group’s transformation.”

There are no further disclosures to be made in connection with Mr Forman’s appointment pursuant to paragraph 9.6.13 of the Financial Conduct Authority’s Listing Rules.

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development group. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2014, Tate & Lyle sales totalled £3.1 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2014

Date   Source Headline
1st Nov 20245:44 pmRNSTransaction in Own Shares
1st Nov 202412:15 pmRNSTotal Voting Rights
31st Oct 20245:28 pmRNSTransaction in Own Shares
30th Oct 20245:33 pmRNSTransaction in Own Shares
29th Oct 20245:27 pmRNSTransaction in Own Shares
28th Oct 20245:40 pmRNSTransaction in Own Shares
28th Oct 20244:30 pmRNSHolding(s) in Company
25th Oct 20245:25 pmRNSTransaction in Own Shares
24th Oct 20245:31 pmRNSTransaction in Own Shares
23rd Oct 20245:19 pmRNSTransaction in Own Shares
23rd Oct 202411:00 amRNSHolding(s) in Company
22nd Oct 20245:28 pmRNSTransaction in Own Shares
22nd Oct 202412:45 pmRNSTotal Voting Rights
21st Oct 20245:36 pmRNSTransaction in Own Shares
18th Oct 20245:46 pmRNSTransaction in Own Shares
17th Oct 20245:40 pmRNSTransaction in Own Shares
16th Oct 20245:20 pmRNSTransaction in Own Shares
15th Oct 20245:23 pmRNSTransaction in Own Shares
14th Oct 20245:29 pmRNSTransaction in Own Shares
11th Oct 20245:38 pmRNSTransaction in Own Shares
10th Oct 20245:36 pmRNSTransaction in Own Shares
9th Oct 20245:26 pmRNSTransaction in Own Shares
8th Oct 20245:32 pmRNSTransaction in Own Shares
7th Oct 20245:41 pmRNSTransaction in Own Shares
4th Oct 20245:58 pmRNSTransaction in Own Shares
3rd Oct 20245:34 pmRNSTransaction in Own Shares
3rd Oct 20247:00 amRNSInformation - combination Tate & Lyle / CP Kelco
2nd Oct 20245:47 pmRNSTransaction in Own Shares
1st Oct 20245:32 pmRNSTransaction in Own Shares
1st Oct 202412:00 pmRNSTotal Voting Rights
30th Sep 20245:25 pmRNSTransaction in Own Shares
27th Sep 20245:49 pmRNSTransaction in Own Shares
26th Sep 20245:33 pmRNSTransaction in Own Shares
25th Sep 20245:33 pmRNSTransaction in Own Shares
24th Sep 20243:00 pmRNSDirector/PDMR Shareholding
23rd Sep 20245:45 pmRNSTransaction in Own Shares
20th Sep 20245:40 pmRNSTransaction in Own Shares
19th Sep 20245:51 pmRNSTransaction in Own Shares
18th Sep 20245:31 pmRNSTransaction in Own Shares
17th Sep 20245:33 pmRNSTransaction in Own Shares
16th Sep 20245:40 pmRNSTransaction in Own Shares
13th Sep 20245:32 pmRNSTransaction in Own Shares
12th Sep 20245:41 pmRNSTransaction in Own Shares
11th Sep 20245:35 pmRNSTransaction in Own Shares
10th Sep 20245:42 pmRNSTransaction in Own Shares
9th Sep 20245:27 pmRNSTransaction in Own Shares
9th Sep 202411:00 amRNSHolding(s) in Company
6th Sep 20245:47 pmRNSTransaction in Own Shares
5th Sep 20245:47 pmRNSTransaction in Own Shares
5th Sep 20241:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.